Message Font: Serif | Sans-Serif
 
No. of Recommendations: 0
DNA +4 afterhours.



5:02PM Genentech: pivotal Herceptin data shows significant improvement in disease-free survival in breast cancer (DNA) 85.00 +0.30:Co announces that The New England Journal of Medicine published data from a joint interim analysis of two pivotal Phase III trials of Herceptin (trastuzumab) plus chemotherapy. The analysis showed that the addition of Herceptin significantly reduced the risk of breast cancer recurrence by 52% in women with early-stage, operable human epidermal growth factor receptor 2 (HER2)-positive breast cancer. After four years, 15% of women treated experienced disease recurrence, compared to 33% treated with chemotherapy alone. HER2-positive breast cancer is an especially aggressive form of the disease that affects 25% of women with breast cancer.

Print the post  

Announcements

What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Community Home
Speak Your Mind, Start Your Blog, Rate Your Stocks

Community Team Fools - who are those TMF's?
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.
Advertisement